navoban 5 mg kapsler, hårde
alkopharma sarl - tropisetronhydrochlorid - kapsler, hårde - 5 mg
navoban 1 mg/ml injektions-/infusionsvæske, opløsning
alkopharma sarl - tropisetronhydrochlorid - injektions-/infusionsvæske, opløsning - 1 mg/ml
farydak
pharmaand gmbh - vandfri vandfri panobinostat - multipelt myelom - antineoplastiske midler - farydak, er i kombination med bortezomib og dexamethason, indiceret til behandling af voksne patienter med recidiverende og/eller ildfaste myelomatose, der har modtaget mindst to tidligere regimer herunder bortezomib og immunmodulerende agent. farydak, er i kombination med bortezomib og dexamethason, indiceret til behandling af voksne patienter med recidiverende og/eller ildfaste myelomatose, der har modtaget mindst to tidligere regimer herunder bortezomib og immunmodulerende agent.
rimactazid 150+75 mg filmovertrukne tabletter
sandoz a/s - isoniazid, rifampicin - filmovertrukne tabletter - 150+75 mg
rimcure 150 mg/400 mg/75 mg filmovertrukne tabletter
sandoz a/s - isoniazid, pyrazinamidum, rifampicin - filmovertrukne tabletter - 150 mg/400 mg/75 mg
rimstar 150+75+400+275 mg filmovertrukne tabletter
sandoz a/s - ethambutolhydrochlorid, isoniazid, pyrazinamidum, rifampicin - filmovertrukne tabletter - 150+75+400+275 mg
rimstar 150+75+400+275 mg filmovertrukne tabletter
orifarm a/s - ethambutolhydrochlorid, isoniazid, pyrazinamidum, rifampicin - filmovertrukne tabletter - 150+75+400+275 mg
rifampar 150+75+400+275 mg filmovertrukne tabletter
paranova danmark a/s - ethambutolhydrochlorid, isoniazid, pyrazinamidum, rifampicin - filmovertrukne tabletter - 150+75+400+275 mg
rimstar 150+75+400+275 mg filmovertrukne tabletter
2care4 aps - ethambutolhydrochlorid, isoniazid, pyrazinamidum, rifampicin - filmovertrukne tabletter - 150+75+400+275 mg
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiske midler - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.